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The aim of this study was to assess the clinical efﬁcacy and safety of oral ginger for symptomatic
treatment of osteoarthritis (OA) by carrying out a systematic literature search followed by meta-analyses
on selected studies. Inclusion criteria were randomized controlled trials (RCTs) comparing oral ginger
treatment with placebo in OA patients aged >18 years. Outcomes were reduction in pain and reduction
in disability. Harm was assessed as withdrawals due to adverse events. The efﬁcacy effect size was
estimated using Hedges' standardized mean difference (SMD), and safety by risk ratio (RR). Standard
random-effects meta-analysis was used, and inconsistency was evaluated by the I-squared index (I2).
Out of 122 retrieved references, 117 were discarded, leaving ﬁve trials (593 patients) for meta-analyses.
The majority reported relevant randomization procedures and blinding, but an inadequate intention-to-
treat (ITT) analysis. Following ginger intake, a statistically signiﬁcant pain reduction SMD ¼ 0.30 ([95%
CI: [(0.50, 0.09)], P ¼ 0.005]) with a low degree of inconsistency among trials (I2 ¼ 27%), and a
statistically signiﬁcant reduction in disability SMD ¼ 0.22 ([95% CI: ([0.39, 0.04)]; P ¼ 0.01; I2 ¼ 0%])
were seen, both in favor of ginger. Patients given ginger were more than twice as likely to discontinue
treatment compared to placebo ([RR ¼ 2.33; 95% CI: (1.04, 5.22)]; P ¼ 0.04; I2 ¼ 0%]).
Ginger was modestly efﬁcacious and reasonably safe for treatment of OA. We judged the evidence to
be of moderate quality, based on the small number of participants and inadequate ITT populations.
Prospero: CRD42011001777.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Ginger has been an important ingredient in Asian medicine for
centuries, particularly for pain relief in musculoskeletal diseases1.
In Europe, ginger was listed in Galen's pharmacopoeia2, and was
mentioned by Plinius the Elder for medicinal use3. Since then,
ginger has been part of the folk medicine and popular nutraceut-
icals. Ginger consists of a complex combination of biologically
active constituents, of which the compounds gingerols, shogoals
and paradols reportedly account for the majority of its anti-o: E.M. Bartels, The Parker
en University Hospital, Bis-
00 Copenhagen F, Denmark.
. Bartels).
ternational. Published by Elsevier Linﬂammatory properties4. However, there is variability in the
compounding of ginger products. The relative composition in the
extraction of ginger is determined by species of ginger, maturity of
the rhizome, climate in which the plants are grown, when har-
vested, and preparation method of the extract5.
Preclinical research has shown that ginger acts as an inhibitor of
cyclooxygenase (COX), particularly the inducible form of COX (COX-
2), rather than the constitutive form (COX-1)6. Ginger also inhibits
lipo-oxygenase, resulting in suppression in the synthesis of the
inﬂammatory leukotrienes7. Various ginger compounds and ex-
tracts have been tested as anti-inﬂammatory agents, where the
length of the side chains determines the level of effectiveness.
However, a combination of ginger extracts is more effective in
decreasing inﬂammatory mediators than an individual compound8.
Ginger extracts are, furthermore, found to inhibit the expression of
tumor necrosis factor (TNF)-a in synoviocytes activated by eithertd. All rights reserved.
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was shown to be as effective an anti-inﬂammatory agent as
betamethasone11.
Today the therapy for osteoarthritis (OA) is still directed towards
symptoms, since no disease-modifying therapy has been estab-
lished, and there is continued research into potential symptom-
modifying drugs with minimal adverse reactions12,13. Apart from
ginger, several other herbal medicines and nutraceuticals have
been studied as alternatives to non-steroidal anti-inﬂammatory
drugs (NSAIDs) in the treatment of OA. Among these are Boswella
serrata, avocadoesoybean unsaponiﬁables (ASU), rosehip, passion
fruit peel extract, and curcuminoids14e21. Use of herbal medicine is,
furthermore, mentioned in the latest OARSI guidelines for non-
surgical management of knee OA22, and a thorough evaluation of
orally taken and topically applied complementary and alternative
medicines in the treatment of OA is given in two systematic reviews
by Long et al.23, and by De Silva et al.24.
With the growing interest in use of herbal and phytochemical
products in the treatment of OA, the aim of this study was to assess
the clinical evidence of efﬁcacy and safety of oral ginger in the
symptomatic treatment of OA, with an emphasis on the quality of
the evidence (i.e., our conﬁdence that the estimates of the effect are
correct).
Methods
A systematic literature search, followed by study selection ac-
cording to pre-speciﬁed eligibility criteria, data extraction, and
statistical analyses, was performed based on a protocol following
the standards of the Cochrane Collaboration (http://www.
cochrane-handbook.org/), and reported according to the PRISMA
statement25. After ﬁnalizing the protocol, it was made publicly
available via PROSPERO (CRD42011001777): www.crd.york.ac.uk/
PROSPERO/.
Retrieval of published literature
The following bibliographic databases were searched up to 24th
April 2014: MEDLINE via PubMed from 1950, EMBASE via OVID
from 1980, CINAHL via EBSCO from 1981,Web of Science from 1900,
and Sciﬁnder from 1907, as well as The Cochrane Central Register of
Controlled Trials. The search strategy was: (Osteoarthritis OR
osteoarthros*) AND (ginger OR zingiber OR gingifere OR ginginer
OR zingiberis OR zinziber) AND (controlled OR placebo). All words
were searched as free text and, where applicable, also as keywords.
Reference lists from reviews were screened for further studies. In
addition, we manually searched the Osteoarthritis Research Society
International conference proceedings for the last 5 years.
Eligibility criteria
Inclusion criteria were: Randomized controlled trials (RCTs)
comparing any oral ginger preparation (consisting only of extracts
of ginger species) with placebo treatment. Participants were pa-
tients aged 18 or over with OA in any joint. Two reviewers (EMB,
VNF) independently evaluated the studies for eligibility. Disagree-
ments were resolved by discussion and/or a consensus meeting
with other authors. No restrictions in language or publication year
were applied.
Quality assessment: risk of bias
Two reviewers (VNF, RC) independently assessed (i) randomi-
zation including both sequence generation and the assessment of
concealment of treatment allocation, (ii) blinding (incl., who wereblinded), and (iii) adequacy of statistical analyses [i.e., proper
intention-to-treat (ITT) analysis]. Randomization and concealment
of allocation were considered adequate if the investigators
responsible for patient selection and inclusion in a study were
unable to predict which treatment was next. Blinding was consid-
ered adequate if participants and study personnel ensured com-
plete lack of knowledge of treatment allocation, and that it was
unlikely that the blinding had been broken during the trial period.
Analyses were considered adequate if all randomized patients were
analyzed in the group to which they were randomly allocated to
regardless of the treatment received (ITT principle). We classiﬁed
trials as violating the ITT principle if they explicitly reported ex-
clusions from the analysis, if the number of patients analyzed was
lower than the number of patients randomized, or if it was unclear
whether exclusions from the analysis had occurred26. Anymodiﬁed
ITT population/analysis was categorized as unclear. Assessment of
each entry involved answering a question, with answer ‘Adequate’
indicating low risk of bias (¼adequate handling/reporting in the
paper), ‘Unclear’ risk of bias (either lack of information or uncer-
tainty concerning the potential for bias), whereas ‘Inadequate’
referred to an inadequate handling of the item (i.e., resulting in a
high risk of bias per se). Disagreements were resolved by consensus
(VNF, RC and EMB).
Data extraction and outcome measures
Data from the included trials were extracted by two reviewers
(VNF and RC). A standard data-extraction form was developed for
data collection. Being aware of the possible inclusion of trials with a
cross-over design, which often will be subjected to carry-over
bias27, only data from the ﬁrst period were included in those
cases. The following information was systematically extracted as
characteristics of the studies for each of the randomized trials and
handled in a customized Microsoft Excel spread sheet: Study
design, ITT population, numbers of patients included in the anal-
ysis, demographic characteristics, joints affected with OA, extrac-
tion technique and origin, study duration, dosage, and risk of bias.
The core-outcome data in each study consisted of the sample
size of the ginger and the placebo group, the number of events in
each group, or the values of continuous outcomes with the corre-
sponding measure of dispersion converted into a feasible standard
deviation in each group at the end of the study, or from change
scores. Change scores were preferable. The co-primary outcome
was change in pain and change in disability28. Safety was assessed
using a pragmatic generic approach29, extracting the number of
withdrawals due to adverse events, serious adverse events, and the
number of patients who discontinued for any reason.
Statistical analysis
Whenever possible we used results from the ITT population. For
the continuous outcomes, pain and disability, we calculated the
standardized mean difference (SMD) for each study30 corre-
sponding to Cohen's d-value31. In principle the unadjusted
(Cohen's) SMD does not treat the variance as an estimate32, thus we
applied the Hedges' bias-correction by default to adjust for small-
sample bias33. The SMDs were signed so that a negative value
(SMD < 0) indicates beneﬁt of ginger treatment. Risk Ratios (RRs)
were calculated for the binary outcomes.
We used standard random-effects meta-analysis34 as default
option, whereas the ﬁxed-effects model was applied for the pur-
pose of sensitivity analysis. We calculated the I2 statistic35 which
describes the percentage of total variation across trials due to
heterogeneity rather than to chance36. For practical reasons we
deﬁned critical inconsistency thresholds as: I2 values below 25%,
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moderate, and high between-trial inconsistency, respectively. We
estimated the Number Needed to Treat in order to Harm (NNH),
with 95% conﬁdence intervals (95% CI) on the basis of the combined
RR value, applying the overall event rate in the placebo groups as a
proxy for baseline risk. All results are given with 95% CIs.
A number of pre-speciﬁed stratiﬁed analyses were executed.
Stratifying the available trial results according to clinically impor-
tant factors and continuous variables at trial level were included in
Restricted Maximum Likelihood (REML)-based (i.e., random-
effects) meta-regression models16. Data were analyzed according
to: Dose (mg/day), accumulated dose (protocolled intakemg during
trial period), trial duration, and OA joint(s) affected. Analyses were
performed using SAS software (version 9.2)37,38.
Results
Study selection
Figure 1 shows the selection process among potentially eligible
studies from the recovered references, following removal of du-
plicates. From the retrieved 122 references, 115 were discarded for
the following reasons: Reviews or outreach papers like editorials,
letters etc (72), in vitro studies (5), animal studies (8), not con-
cerning OA (9), no placebo or not a controlled study (6), and ﬁnally
not concerning oral ginger intake (15). Seven references were read
in full-text, and two of those were discarded; one due to no oral
ginger intake39, and one due to no placebo40. Five studies were
ﬁnally included in the meta-analysis41e45.Fig. 1. Flow chart showing the selection of trials. RCTs: Randomized controlled trials.Study characteristics
Table I shows the characteristics of the ﬁve selected trials. Two
studies42,43 had a study design with three arms, one of which was
ibuprofen treatment. Two of the trials42,44 used a cross-over design,
thus only data from the ﬁrst period of these trials was included in
the statistical analyses. The number of patients in the ITT popula-
tion, taking the mentioned study design into account, is displayed
in Table I. In total, the ﬁve trials allocated 757 patients to ginger or a
placebo-control group. Due to a large drop-out, only 593 patients
from the ﬁve included studies were included in the primary anal-
ysis (i.e., pain). Thus the ITT populations available for the meta-
analyses was characterized as inappropriate, since the inﬂuence
of potential attrition bias is not included and cannot be adjusted for
in the subsequent meta-analysis. Three trials41,44,45 included pa-
tients with OA of the knee only, one trial42 included patients with
OA of the knee or the hip, and one trial43 gave no information on
type of OA joint.
The average age of the patients ranged from 47 years to 66 years,
and the percentage of women included in the studies ranged from
26% to 80%. The daily dose of oral administration of ginger ranged
from 500 mg/day to 1000 mg/day. Furthermore, the ginger prod-
ucts varied between studies. Even the two studies based on the
same patent Eurovita extract 33 and extract 77 had a slightly
different composition of the non-ginger content41,42, although the
extraction method was the same and the ginger composition
should be the same, while the other products were produced by
different extraction methods and ginger species compositions43,44,
and one study did not describe the extraction method45. Trial
duration ranged from 3 to 12 weeks, resulting in a calculated
accumulated dose ranging from 10,710 mg to 84,000 mg. The ﬁve
trials had an adequate or unclear reporting of allocation conceal-
ment. The majority had an adequate quality of blinding, whereas all
the studies applied an unclear or inadequate use of the ITT popu-
lation (see Table I: ‘Risk of Bias’).
Efﬁcacy
Figure 2(A) shows the SMD on pain reduction when comparing
ginger with placebo. Combining the data from the ﬁve individual
trials (593 patients in total), reporting pain as an outcome, pro-
duced a combined SMD of 0.30 (95% CI: 0.50 to 0.09,
P ¼ 0.005), supporting a statistically signiﬁcant difference in the
efﬁcacy of ginger compared to placebo. The result is based on
studies showing a modest degree of inconsistency (I2 ¼ 27%). As
expected from the reasonably consistent results, the corresponding
analysis based on a Fixed Effects model revealed about the same
clinical effect (SMD ¼ 0.28 [95% CI: 0.47 to 0.08, P ¼ 0.0008]).
To ensure that this effect size would actually be statistically sig-
niﬁcant, and that the precision of the estimate was reasonable, we
calculated the ‘Optimal Information Size’ (OIS)46 as the number of
patients required for an adequately powered individual trial with
an SMD ¼ 0.30. For a two-sample pooled t-test, with a statistical
signiﬁcance level of 5%, a total sample size of 352 patients in a
balanced design (1:1) would be required to obtain a power of at
least 80%. As the ‘pain meta-analysis’ meets the OIS criterion (data
from 593 patients), there is no reason to downgrade the quality of
evidence for imprecision.47,48
Figure 2(B) shows the SMD on disability reduction with ginger
vs placebo. When combining the data from the four individual
trials41,42,44,45 (513 patients in total), self-reported disability
showed a statistically signiﬁcant combined SMD of 0.22 (95%
CI: 0.39 to 0.04, P ¼ 0.01). This supports efﬁcacy of ginger
compared to placebo. The result is based on studies with apparently
no inconsistency (I2 ¼ 0%), and the corresponding Fixed Effects
Table I
Characteristics of eligible trials
Study Year Design N
(Ginger)
N
(Placebo)
Age
(years)
Females
(%)
Knee/hip Extraction technique and origin Trial
duration
(weeks)
Daily dose
(mg/day)
Accumulated
dose (mg total)
Risk of
bias
Bliddal 2000 CO 19 19 66* 41 (73%)* 36/20* Extract of Chinese ginger
(Eurovita Extract 33) with a
standardized content of
hydroxyl-methoxy-phenyl
compounds. Extraction method
U.S. Patent Number: 6.638.525
3 510 10,710 A/A/C
Altman 2001 PG 124 123 65y 151 (61%)y 247/0y Extract of dried ginger rhizomes
and dried galanga rhizomes
(Eurovita Extract 77) with a
content of hydroxyl-methoxy-phenyl
compounds. Extraction method U.S.
Patent Number: 6.638.525.
6 510 21,420 A/A/B
Wigler 2003 CO 11 13 62z 23 (79%)z 29/0z Liquid carbon dioxide extraction of
Zingiber ofﬁcinale
12 1.000 84,000 B/A/C
Haghighi 2005 PG 40 40 59x 31 (26%)x n.a./n.a 95 % ethanol extraction of Zingiber
ofﬁcinale Rosce
4 1.000 28,000 B/B/B
Zakeri 2011 PG 103 101 47y 164 (80%)y 204/0y Extract of Zingiber ofﬁcinale,
Zingibraceae. Extraction method
not described
6 500 21,000 B/A/C
CO: Cross-over design. PG: Parallel-group design. ITT Population: All randomized individuals. N (Ginger): Numbers of patients included in analysis of the experimental (ginger)
group. N (Placebo): Numbers of patients included in analysis of the control (placebo) group.
* Numbers based on 56 patients reported evaluable.
y Numbers based on patients included in the analysis.
z Numbers based on ITT-population.
x Numbers based on 120 patients randomized in three treatments groups of 40; ginger extract, placebo and ibuprofen. Knee/Hip: Numbers of joints affected with OA in
either knee or hip. n.a.: Data not speciﬁed/available. Risk of bias was assessed as (i) randomization including both sequence generation and the assessment of concealment of
treatment allocation, (ii) blinding (incl., who were blinded), and (iii) adequacy of statistical analyses (i.e., proper ITT analysis). A ¼ adequate; B ¼ unclear; C ¼ inadequate.
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CI: 0.39 to 0.04, P ¼ 0.01). In terms of the OIS criteria, the
number of patients required for an adequately powered individual
trial with an SMD ¼ 0.22 would be a total sample size of 652 pa-
tients to obtain a power of at least 80%. As the ‘disability meta-
analysis’ did notmeet the OIS criterion (data from 513 patients), it is
reasonable to downgrade the quality of the evidence for
imprecision.Fig. 2. Efﬁcacy forest plots of trials comparing ginger with placebo in OA patients shown as S
by a square, with 95% CIs indicated by horizontal lines. The total estimate and the correspoThe results from the stratiﬁed and meta-regression analyses
based on our primary outcome (pain reduction) with ginger
vs placebo are presented in Table II: Estimates of SMDs varied to a
large degree between the studies with an adequate blinding
(SMD 0.21) and the study with an unclear blinding
(SMD ¼ 0.76), i.e., the clinical effect size could be more exagger-
ated in trials using an inappropriate masking technique warranting
a downgrading for risk of bias. There was a statistically signiﬁcantMD for (A) pain and (B) disability. The individual trial's effect measures are represented
nding 95% CI are represented by diamonds at the bottom of each forest plot.
Table II
Results of the stratiﬁed and meta-regression analyses.*
Variable Total trials, k ES, SMD (95% CI) t2 I2 P-value for
interaction
All studies 5 0.30 (0.51 to 0.08) 0.017 27% n.a.
Study design 0.032 52% 0.60
Cross-Over 2 0.17
Parallel group 3 0.34
%Females 0.010 16% 0.11
Slope n.a. 0.0088 (0.002 to 0.019)
Intercept n.a 0.85 (1.56 to 0.15)
Ginger extract 0.022 35% 0.23
Eurovita extract 2 0.14 (0.48 to 0.19)
Other 3 0.42 (0.73 to 0.12)
Trial duration (wks) 0.021 34% 0.75
Slope n.a. 0.02 (0.09 to 0.13)
Intercept n.a. 0.40 (1.08 to 0.28)
Daily dose (mg/d) 0.000 0% 0.04
Slope n.a. 0.00092 (0.0018 to 0.00004)
Intercept n.a 0.26 (0.28 to 0.81)
Accumulated dose (mg) 0.018 29% 0.61
Slope n.a. 0.00 (0.00002 to 0.00001)
Intercept n.a. 0.21 (0.61 to 0.20)
Risk of bias:
Allocation conc. 0.022 35% 0.23
Adequate 2 0.14 (0.48 to 0.19)
Unclear 3 0.42 (0.73 to 0.12)
Inadequate 0 e e
Blinding 0.000 0% 0.03
Adequate 4 0.21 (0.37 to 0.03)
Unclear 1 0.76 (1.22 to 0.30)
Inadequate 0 e e
ITT analysis 0.048 77% 0.53
Adequate 0 e e
Unclear 2 0.40 (0.78 to 0.01)
Inadequate 3 0.22 (0.61 to 0.16)
Data are based on the number of patients (n¼ 593) included in the primary analysis (i.e., pain). k: Numbers of sub-studies. ES: Effect size. SMD: Standardized mean difference.
CI: Conﬁdence interval. t2: Tau-squared (between-study variance). I2: Inconsistency index (measuring heterogeneity). ITT: Intention to treat. n.a. not applicable.
* All analyses presented are based on REML (random effects) meta-analysis approach.
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be a relevant study-level covariate reducing the between study
variation. The statistically signiﬁcant slope supports upgrading of
the quality of the evidence (more conﬁdence in the estimates) with
a biologically plausible doseeresponse association, providing us
with more conﬁdence in the estimate.
Safety
Of the ﬁve included trials, only three41,42,44 reported usable data
on safety (328 patients in total). Figure 3 shows a statistically
signiﬁcantly increased risk of withdrawals due to adverse events
among patients allocated to ginger compared to placebo, with an
RR ¼ 2.33 (95% CI: 1.04e5.22; P ¼ 0.04; I2 ¼ 0%). The reported
adverse events were though all related to bad taste or various forms
of stomach upset, and none could be classiﬁed as ‘serious’ in terms
of causing lasting harm, although they made the patients uncom-
fortable enough to decide to discontinue treatment. This combined
estimate is based on (assumed) consistent ﬁndings (I2 ¼ 0%). The
NNH for ginger corresponds to 15 (95% CI: 5e500) patients. Forest
plot andmeta-analysis of all cause discontinuation (three trials and
610 patients; data not shown) presented a slightly increased risk
among patients allocated to ginger compared to placebo, with an
RR ¼ 1.26; 95% CI: (0.83e1.93). This was though not statistically
signiﬁcant (P ¼ 0.11; I2 ¼ 54%). Only one trial32 contributed to theanalysis of serious adverse events (data not shown), with an RR of
0.33 (95% CI: [0.01e7.70]; P ¼ 0.49; I2 not applicable).
Discussion
Based on the empirical evidence, our data supports that oral
ginger is able to reduce pain and disability in OA46. Our conﬁdence
in the clinical beneﬁt and the optimal therapeutic dose is though
moderate based on a double downgrading for Risk of Bias (i.e.,
serious limitations in the applicable ITT population estimates), and
a subsequent upgrading due to the apparent doseeresponse
relationship49.
This review is based on the rigorous standards of the ‘Method-
ological Expectations for Cochrane Intervention Reviews’ (MECIR)
and reported according to the PRISMA statement, and we believe
this has minimized the potential for bias25. The presented quanti-
tative analyses have been generated according to state of the art
meta-analysis methodology30, resulting in anticipated unbiased
estimates.
The SMD of 0.30 for ginger compared with placebo corre-
sponds to an effect size for pain which is only slightly above the
critical threshold limit for a relevant SMD in OA31, and it is com-
parable, although a little higher, to the SMD of 0.21 seen with
intake of acetaminophen50. The observed pain reducing effect for
ginger is in the same range as SMD previously reported for other
Fig. 3. Safety forest plot of trials comparing ginger with placebo in OA patients represented as RR for adverse events. The individual trial's effect measures are represented by a
square, with 95% CIs indicated by horizontal lines. The total estimate and the corresponding 95% CI are represented by a diamond at the bottom of the forest plot.
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of 0.2451, ASUs with an SMD of 0.3916, and rose hip powder
of 0.3717, all in comparison with placebo. Compared to the effect
of NSAIDs, the SMD for ginger has an effect size in the middle of the
NSAID range of 0.17 to0.66, all when compared to placebo52e54.
Since OA is a chronic disease with increasing need of treatment,
it is important to ﬁnd a right balance between beneﬁt and harm
with long term use of any applied treatment55. NSAIDs are
commonly used in OA, but serious cardio-vascular and gastro-
intestinal adverse effects of this group of drugs are well-
known13,56. Ginger is, on the other hand, generally considered safe,
and no serious adverse effects were seen when ginger extract was
given to rats57,58. Main complaints with ginger intake are milder
stomach upset, ‘bad taste in themouth’, and similar59,60, which also
are the mentioned adverse effects which lead to withdrawal from
treatment in the included studies in this meta-analysis. Ginger
therefore seems a better treatment option than NSAIDs judged on
possible adverse effects of the latter treatment. There could though
be other concerns like allergy caused by the ginger preparations,
and interactions with medication.
When looking at allergic reactions caused by ginger, a study
demonstrated that ginger did not produce allergic reactions tested
by prick-tests61. In contrast, extract from common ginger in an
in vitro study showed a small, although insigniﬁcant, anti-allergenic
effect62.
It is well-documented that ginger is an anti-coagulant, and this
will be of importance in connection with patients taking drugs like
warfarin59,63,64. A particular important ﬁnding is the synergistic
effect between ginger and nifedipine on anti-platelet aggrega-
tion65. Since OA patients in general are older subjects who are often
overweight to obese, a subpopulation with a heart condition or
high blood pressure can be expected. Recommendation on trying
ginger as a therapy has therefore to take a possible interaction of
ginger with the patients' other medication into account prior to
recommending use of ginger.
Limitations
Even though wewere comprehensive in our search strategy, the
risk of publication bias is still present. Poor results or industrial
inﬂuence tend to affect the probability of trials being published,and trials with positive ﬁndings are more likely to be published
than trials with negative or null ﬁndings66. Our study is limited by
the inadequate reporting in the included trials. Only two trials41,42
reported adequate allocation of concealment, and three trials43e45
were unclear in randomization and concealed allocation.
Four trials41,42,44,45 reported adequate blinding, and one trial43
was unclear. Trials with adequate allocation of concealment and
adequate blinding tend to show a smaller treatment beneﬁt than
trials with unclear or inadequate allocation of concealment and
blinding67. It is likely that our results overestimate the treatment
beneﬁt. This is especially due to unclear allocation of conceal-
ment68. Selective outcome-reporting bias is also likely in this ﬁeld
of research. Despite the use of a rigorous protocol for the selection
of the outcomes included in the meta-analysis, this tends to lead to
overestimation28.
Ginger has a characteristic taste and ﬂavor which questions the
possibility of adequate blinding. Only one study describes the effort
to minimize bias via instructions to the patients on how to swallow
the capsules, and this study also reports a registration of the
number of cases with bad taste42. The risk of bias due to taste and
ﬂavor cannot, however, be ruled out in any of the trials, since any
patient experiencing ‘bad taste in the mouth’ may suspect being in
the ginger group of the study, which in itself may cause a placebo
effect. Another problem is the different ginger preparation in the
included studies. Taste and content of active ginger components
may vary, but there are no studies comparing these between the
included products. In most trials on nutritional products, the lack of
knowledge of the actual content of the active component, and, like
for ginger, the lack of knowledge of the comparability between the
different products used in the studies included in the meta-
analysis, will therefore always put a question mark concerning a
possible bias in the reported results.
All trials in our study applied an unclear/inadequate use of the
ITT population, which possibly lead to attrition bias due to not
including the per-protocol planned population. Empirical evidence
shows that excluding randomized participants from the analysis
affects the estimates of the treatment effect and increases the
heterogeneity between trials26. Previous systematic reviews of the
clinical effectiveness of ginger, one on OA patients69, and one on
trials using oral ginger for pain treatment60, did not conduct meta-
analyses. The ﬁrst review69 did not carry out a meta-analysis due to
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exclusion of the Altman et al. study42 due to use of a combined
ginger preparation. In the second review60, a meta-analysis was not
conducted due to heterogeneity between studies. In the present
study, original data was acquired from the authors42, and a review
of the registered extraction methods lead to an inclusion of the
Altman et al. trial41. Thus, the total available data was adequate to
conduct a meta-analysis.
In the studies included in our meta-analysis, all preparations are
basedon the samespecies of ginger, but theextractionmethods, apart
from the two Eurovita preparations with similar type of extraction,
vary. The content of active components, especially gingerols, shogoals
and paradols4, are therefore likely to vary70e73, and the composition
of the different components in 1 g of ‘ginger’ is not necessarily well-
deﬁned. This will always be an issue with neutraceuticals of the
same kind coming fromdifferent producers. The content of the active
componentmay vary, and if one product has an optimal composition
for effect on pain compared to the others, the results presented here
may not give such a product full credit for effect.
Herbal remedies and other nutraceuticals are increasingly and
extensively used by a substantial part of the population74e78. Un-
fortunately only few of the remedies have been tested for efﬁcacy
and safety in well-designed clinical trials.
Recent recommendations from the American College of Rheu-
matology (ACR) on therapies for OA of the hand, hip, and knee are
based on consensus judgment of available evidence, and balancing
the beneﬁts and harms of both non-pharmacologic and pharma-
cologic modalities. The ACR provides a weak (conditional) recom-
mendation for most pharmacologic modalities in the initial
management of patients with knee OA. These include acetamino-
phen (paracetamol), oral and topical NSAIDs, tramadol, and intra-
articular corticosteroid injections, intra-articular hyaluronate in-
jections, duloxetine, and opioids79.
The present meta-analysis on ginger for OA demonstrated that
ginger has a superior effect on OA pain and disability to placebo,
and apparently without serious adverse events. As a conclusion,
ginger may be considered as part of the treatment of OA, where the
patient is motivated for trying this nutraceutical. As with other
complementary and alternative therapies, further studies from
independent researchers would be able to show if the effects sug-
gested by the present data will stand in the future. Also, as in all
treatment of patients which may take other medication, known
possible interaction between medicine and nutraceuticals must be
considered.
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